From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India's Top-Selling Drug
New Delhi: Eli Lilly's diabetes and obesity drug Mounjaro (Tirzepatide) has become India's top-selling drug by value for October 2025, overtaking long-time leaders in the antidiabetic and cardiac therapy segments, according to the latest PharmaTrac Industry Mailer and IPM Performance Report for MAT October 2025.
As per PharmaTrac and industry data, Mounjaro recorded nearly ₹100 crore in sales in October 2025, the highest for any brand that month in the Indian Pharmaceutical Market (IPM). This puts it ahead of traditional market leaders such as Augmentin, which posted around ₹80 crore, and other top brands like Glycomet GP and Dolo-650.
Since its March 2025 launch, the GLP-1 receptor agonist has generated a cumulative ₹333 crore, marking one of the fastest scale-ups ever achieved by a new injectable antidiabetic in India.
The IPM grew 9.5 per cent by value in October 2025, with the antidiabetic therapy segment continuing to lead overall growth. The category recorded ₹21,734 crore in MAT value and 12.5 per cent monthly growth, driven by the strong uptake of next-generation incretin drugs such as Mounjaro (Tirzepatide) and Ozempic (Semaglutide).
PharmaTrac data indicates that Mounjaro’s unit sales crossed 2.6 lakh doses in October, with each monthly treatment priced between ₹14,000 and ₹27,500, depending on strength and pack size. Despite lower volume than many oral antidiabetics, Mounjaro’s high per-unit value propelled it to the top in overall revenue contribution.
The drug’s rapid growth has also boosted Eli Lilly’s position in the Indian market, helping the company register one of its strongest ever months since entry. The performance reflects growing physician preference for GLP-1 and dual GIP-GLP-1 agonists and rising adoption among both diabetes and obesity patients.
Medical Dialogues had earlier reported that Mounjaro became India’s second-highest-selling drug by value within six months of launch, generating ₹233 crore in sales by September 2025 — a record for any newly introduced injectable antidiabetic.
Read Also: Rs 233 Crore in 6 Months: Mounjaro Becomes India’s Second Biggest Drug by Sales
Following this milestone, Eli Lilly expanded its reach through a licensing deal with Cipla, which launched the brand under the name Yurpeak, broadening patient access and strengthening the company’s presence in the obesity-care segment.
Read Also: Eli Lilly’s Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal
The October 2025 PharmaTrac report further shows that the GLP-1 and SGLT-2 classes continue to drive therapy-level expansion, with Mounjaro, Ozempic, and Jardiance leading the value chart. Analysts highlight that this surge marks a structural shift in India’s diabetes treatment market from traditional oral agents to novel injectable therapies backed by robust clinical outcomes.
